Note: PCOS was officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) in May 2026. This article uses PCOS throughout while the transition is underway. Read our full article on the renaming here.
The short version
Abdominal weight gain in PCOS is driven by specific hormonal mechanisms: insulin resistance directing fat storage toward the abdomen, and elevated androgens promoting the same pattern. The fat that accumulates is predominantly visceral, meaning it sits inside the abdominal cavity around the organs rather than beneath the skin. This carries metabolic implications beyond the appearance, and it deserves a specific clinical response rather than generic dietary advice.
Why PCOS Changes Where Fat Is Stored
Body fat distribution is not random. It is regulated, and the hormonal environment has a direct influence on where the body preferentially deposits fat. In women without PCOS, oestrogen and normal androgen levels tend to favour subcutaneous fat storage in the hips, thighs, and gluteal region. This is sometimes called the gynoid fat distribution pattern, and while it may not always be welcome aesthetically, it is metabolically not so harmful.
In PCOS, two mechanisms shift this pattern toward the abdomen. First, insulin resistance drives elevated insulin levels, which promotes fat storage in the abdominal region specifically. Second, elevated androgens, particularly testosterone, promote the android fat distribution pattern typically associated with men, where fat accumulates around the waist rather than the lower body. Both mechanisms are operating simultaneously in most women with PCOS, which is why abdominal weight gain is such a consistent and frustrating feature of the condition.
What Kind Of Fat Is It?
The distinction between subcutaneous and visceral fat matters clinically. Subcutaneous fat sits just beneath the skin and can be pinched. It is metabolically relatively quiet. Visceral fat sits inside the abdominal cavity, surrounding the liver, pancreas, intestines, and other organs. It is biologically active: it releases inflammatory molecules and free fatty acids directly into the circulation, contributing to insulin resistance, elevated triglycerides (blood fats), and increased cardiovascular risk.
These risks are not abstract. Women with PCOS already carry elevated long-term risk for type 2 diabetes and cardiovascular disease through the mechanisms of insulin resistance and chronic inflammation. Visceral fat accumulation amplifies those risks. It also worsens insulin resistance in a self-reinforcing loop: more visceral fat drives more insulin resistance, which promotes more visceral fat storage.
A woman with PCOS can be at a medically normal weight while carrying a disproportionate amount of visceral fat. The scale will not show this. BMI will not show this. It requires body composition assessment to see it clearly, which is one of the reasons scale weight alone is a particularly inadequate monitoring tool in this condition.
Why Standard Measures Miss It
BMI and scale weight measure total mass. They cannot distinguish fat from muscle, subcutaneous fat from visceral fat, or a healthy metabolic profile from a significantly elevated-risk one. Two women can share the same BMI while having entirely different visceral fat loads and entirely different cardiometabolic risk profiles.
Waist circumference is a simple, inexpensive, and clinically meaningful addition to monitoring in PCOS. Body composition assessment, which can estimate visceral fat levels, lean mass, and fat distribution over time, provides a more complete picture still. We cover what body composition monitoring involves in our Body Composition Scans page.
What Helps
The most evidence-supported interventions for visceral fat in PCOS target the insulin resistance that drives its accumulation. Dietary approaches that reduce the insulin load, adequate protein, fibre, healthy fats, and limited refined carbohydrates, improve insulin sensitivity over time. Resistance exercise builds lean muscle mass, which is metabolically active tissue that further improves insulin sensitivity at rest. Even modest weight loss of five per cent of body weight produces measurable reductions in visceral fat and improvements in the hormonal features of PCOS.
Where insulin resistance is significant and lifestyle intervention alone is insufficient, medication may be part of the clinical picture. Metformin, and in some cases GLP-1 receptor agonists, address insulin resistance directly and can support both visceral fat reduction and broader hormonal improvement. Individual suitability requires clinical assessment.
For the full overview of PCOS, including diagnosis, treatment options, mental health, sleep, and fertility, read our PCOS And Weight Management: Everything You Need To Know master blog.
This article is general information only and not personal medical advice. Obesity assessment and treatment decisions should be made with a qualified health professional after individual clinical assessment. Not all treatments are suitable for every person.
Looking Forward
Belly fat in PCOS is not a cosmetic problem and it is not a behaviour problem. It is a metabolic consequence of specific hormonal mechanisms, and it responds best to clinical management that addresses those mechanisms directly. If abdominal weight gain has been a persistent feature of your experience with PCOS, a clinical assessment that includes body composition monitoring and metabolic evaluation is the right starting point.
Evidence Notes
Xu, Y., & Qiao, J. (2022). Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): a review of literature. Journal of Healthcare Engineering, 2022, 9240569. https://doi.org/10.1155/2022/9240569
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023). Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. Journal of Ovarian Research, 16(1), 9. https://doi.org/10.1186/s13048-022-01091-0
